Presage Biosciences, a Seattle, Wash.-based company that identifies clinically viable oncology drug combinations, has entered into a cancer research agreement with Millenium, Takeda’s oncology arm based in Cambridge, Mass.

Presage will receive upfront fees and research funding, as well as development and regulatory milestones related to identification of successful drug combinations. In return, Millennium with gain access to Presage’s proprietary technology platform to enable non-clinical identification of effective novel oncology drug combinations in solid tumors.

The patented Presage platform allows for the comparison of multiple drugs in the same tumor within a preclinical model. The technology has potential for application across the drug development process, from target identification to clinical trial patient selection.

“Presage’s technology platform allows us to obtain in-depth non-clinical in vivo data that is typically difficult to gather by conventional approaches,” said Joseph B. Bolen, Ph.D., chief scientific officer, Millennium. “It is our hope that the Presage platform will help us to more rapidly and accurately prioritize our development of novel combinations.”